LadRx is a biopharmaceutical research and development company specializing in oncology. The Company’s focus is on the discovery, research and clinical development of novel anti-cancer drug candidates that employ novel technologies that target chemotherapeutic drugs to solid tumors and reduce off-target toxicities. During 2017, the Company’s discovery laboratory in Freiburg, Germany synthesized and tested over 75 rationally designed drug candidates with highly potent anti-cancer payloads, culminating in the creation of two distinct classes of compounds. Four lead candidates (LADR-7 through LADR-10) were selected based on in vitro and animal studies in several different cancer models, and based on stability and manufacturing feasibility. In addition, a novel companion diagnostic, ACDx™, was developed to identify patients with cancer who are most likely to benefit from treatment with these drug candidates. However, the Company’s research and development activities have been curtailed as they seek additional financing.
Company profile
Ticker
LADX
Exchange
Website
CEO
Steven A. Kriegsman
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CYTRX CORP
SEC CIK
Corporate docs
Subsidiaries
Centurion BioPharma Corporation ...
IRS number
581642750
LADX stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
27 Mar 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K/A
Departure of Directors or Certain Officers
12 Oct 23
8-K
Material Modifications to Rights of Security Holders
11 Sep 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
ARS
2022 FY
Annual report to shareholders
28 Jul 23
DEF 14A
Definitive proxy
28 Jul 23
PRE 14A
Preliminary proxy
17 Jul 23
8-K
LadRx Completes Non-Dilutive Financing Transaction for up to $11 Million with XOMA Corporation
26 Jun 23
10-Q
2023 Q1
Quarterly report
15 May 23
Latest ownership filings
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
4
Joel K Caldwell
29 Jan 24
4
Cary J Claiborne
29 Jan 24
4
Jennifer K. Simpson
29 Jan 24
4
JOHN Y CALOZ
29 Jan 24
4
Stephen Snowdy
29 Jan 24
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 23
3
Cary J Claiborne
28 Jul 22
SC 13G
ARMISTICE CAPITAL, LLC
15 Feb 22
4
Stephen Snowdy
12 Jan 22
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 2.93 mm | 2.93 mm | 2.93 mm | 2.93 mm | 2.93 mm | 2.93 mm |
Cash burn (monthly) | 223.30 k | 6.86 k | 280.10 k | 324.35 k | 223.30 k | (no burn) |
Cash used (since last report) | 1.33 mm | 40.90 k | 1.67 mm | 1.93 mm | 1.33 mm | n/a |
Cash remaining | 1.60 mm | 2.89 mm | 1.26 mm | 999.22 k | 1.60 mm | n/a |
Runway (months of cash) | 7.2 | 421.7 | 4.5 | 3.1 | 7.2 | n/a |
Institutional ownership, Q3 2022
2.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 1 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 1.00 k |
Total shares | 14.30 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
First Heartland Consultants | 14.30 k | $1.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Jan 24 | John Y Caloz | Stock Option Common Stock | Grant | Acquire A | No | No | 1.83 | 15,000 | 27.45 k | 15,000 |
15 Jan 24 | Stephen Snowdy | Stock Option Common Stock | Grant | Acquire A | No | No | 1.83 | 25,000 | 45.75 k | 25,000 |
15 Jan 24 | Joel K Caldwell | Stock Option Common Stock | Grant | Acquire A | No | No | 1.83 | 5,000 | 9.15 k | 5,000 |
15 Jan 24 | Cary J Claiborne | Stock Option Common Stock | Grant | Acquire A | No | No | 1.83 | 5,000 | 9.15 k | 5,000 |
15 Jan 24 | Simpson Jennifer K. | Stock Option Common Stock | Grant | Acquire A | No | No | 1.83 | 5,000 | 9.15 k | 5,000 |